Related Experiment Videos
Comparison of buprenorphine and methadone maintenance in opiate addicts
1Department of General Psychiatry, University Hospital of Psychiatry, Währinger Gürtel, Vienna, Austria. drogenambulanz@akh-wien.ac.at
Abstract:
As a maintenance agent for opioid dependency, buprenorphine offers advantages such as a lower level of dependence and minimal withdrawal symptoms, due to its partial agonist properties at the micro-opioid receptor. Previous studies have shown 8 mg sublingual buprenorphine to be equivalent to 60 mg oral methadone in terms of retention rate and opioid-negative urine levels. In a 24-week, ongoing European study, 34 opioid-dependent subjects were assessed; 16 receiving buprenorphine and 18 methadone. A free dosing schedule was used with no upper limit for methadone dosing but with a maximum buprenorphine dose of 8 mg. Screening prior to the study excluded subjects with polysubstance dependence, somatic disease and/or HIV infection. Primary outcome measures were abstinence from other drugs, for which subjects provided weekly urine samples for analysis of opioids, cocaine and benzodiazepines, and retention in treatment. Patients in the buprenorphine group provided a greater proportion of negative urine samples, in particular cocaine-negative samples, compared with the methadone group, although this was not statistically significant. Retention in the buprenorphine group was significantly lower than in the methadone group, suggesting that the 8 mg buprenorphine limit may have biased the results in favour of methadone, and that this dose may have been too low for those subjects with high levels of dependence. However, buprenorphine is clearly effective in the more motivated subjects and further investigation in this subgroup is recommended.
Insights
Buprenorphine, an opioid dependency treatment, showed promise for drug abstinence but had lower retention rates than methadone. The 8 mg buprenorphine dose may have been too low for some patients.
Area of Science:
- Pharmacology
- Addiction Medicine
- Clinical Research
Background:
- Buprenorphine is a partial micro-opioid receptor agonist used for opioid dependency maintenance.
- It offers potential advantages like lower dependence and milder withdrawal symptoms compared to full agonists.
- Prior research suggested 8 mg sublingual buprenorphine efficacy comparable to 60 mg oral methadone.
Purpose of the Study:
- To compare the efficacy of buprenorphine and methadone in treating opioid-dependent subjects.
- To assess treatment retention and drug abstinence rates in patients receiving either buprenorphine or methadone.
Main Methods:
- A 24-week European study involving 34 opioid-dependent subjects (16 buprenorphine, 18 methadone).
- Free dosing schedule used, with a maximum buprenorphine dose of 8 mg and no upper limit for methadone.
- Primary outcomes included drug abstinence (weekly urine analysis for opioids, cocaine, benzodiazepines) and treatment retention.
Main Results:
- The buprenorphine group had a higher proportion of drug-negative urine samples, particularly for cocaine, though not statistically significant.
- Treatment retention was significantly lower in the buprenorphine group compared to the methadone group.
- The 8 mg buprenorphine dose limit may have influenced results, potentially being insufficient for highly dependent individuals.
Conclusions:
- Buprenorphine demonstrates effectiveness in treating opioid dependency, particularly in more motivated individuals.
- Further research is recommended to investigate buprenorphine's efficacy in specific patient subgroups.
- The maximum 8 mg dose of buprenorphine may require adjustment for optimal outcomes in certain patient populations.